- Active not recruitingPHASE3
Detect V / CHEVENDO (Chemo vs. Endo)
This study compares different treatments for advanced breast cancer that has spread. It aims to see if a combination of targeted therapies and hormone therapy works better than targeted therapies and chemotherapy, while also keeping quality of life high.
For: Metastatic Breast CancerGermany - RecruitingPHASE1
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
This study looks at a new combination treatment for advanced breast cancer. It combines a special radiation drug ([177Lu]Lu-NeoB) with two existing medicines (ribociclib and fulvestrant) to see if it's safe and effective, especially for patients whose cancer has come back or worsened after previous hormone treatments.
For: Breast CancerUnited States · China · France - Active not recruitingPHASE3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
This study looks at new ways to treat prostate cancer that hasn't spread but is at medium risk of doing so. It uses a gene test to decide if less or more intense treatment might be better, hoping to reduce side effects or improve outcomes.
For: Prostate AdenocarcinomaUnited States · Canada - Not yet recruitingPHASE2
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
This study looks at a new drug, imlunestrant, for premenopausal women with a common type of early breast cancer. Researchers want to see how it affects cancer cells and the ovaries, comparing it to an existing treatment called tamoxifen. It’s for women whose breast cancer is sensitive to hormones.
For: Breast NeoplasmsUnited States · Belgium · France